Evgen Pharma PLC Early data for SFX-01 in leukaemia cell lines
13 Julio 2021 - 1:00AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
13 July 2021
Evgen Pharma plc
("Evgen" or "the Company")
Early data for SFX-01 in leukaemia cell lines
Evgen Pharma plc (AIM: EVG), the clinical stage drug development
company developing sulforaphane based medicines for the treatment
of multiple diseases, announces preclinical data demonstrating that
SFX-01 was effective in in vitro models of certain blood
cancers.
The data were generated by Dr Eleni Louka and Professor Adam
Mead of the MRC Weatherall Institute of Molecular Medicine at
Oxford University. The study investigated the effect of SFX-01 on
cells from tissue donated by patients with Juvenile Myelomonocytic
Leukaemia ("JMML"), through the UK Paediatric MDS/JMML study. These
patients carry a specific mutation of the PTPN11 gene. The data
demonstrated significant reduction of cell proliferation and
increased apoptosis (cell death) of JMML stem cells in the presence
of SFX-01, compared to normal controls. The study also showed that
SFX-01 significantly impacted cell proliferation and increased
cytotoxicity in GDM-1 cells, an Acute Myelomonocytic Leukaemia cell
line ("AML").
Whilst this is preliminary data from a small sample size, the
Company was encouraged to observe a statistically significant
effect in reducing cell proliferation and increasing apoptosis.
The PTPN11 gene codes for the SHP2 protein (Src homology-2
domain-containing protein tyrosine phosphatase-2). In January,
Evgen announced in-vitro and in-vivo data generated by Professor
Philip Eaton, Queen Mary University of London, demonstrating that
SFX-01 modifies SHP2. Mutations of the PTPN11 gene are among the
commonest molecular defects described in JMML patients, indicating
that SFX-01 should be investigated further as a potential disease
modifying agent in PTPN11-mutated haematological malignancies.
The Company is now assessing the optimal preclinical and
clinical strategy for a development programme of SFX-01 in blood
cancers such as JMML and AML and will update shareholders when this
is completed.
Dr Huw Jones, CEO of Evgen Pharma, commented: "The data from
Oxford and Queen Mary's shows a very exciting opportunity to extend
our oncology pipeline by adding blood cancers to the ongoing
metastatic breast cancer and glioblastoma programmes. We are
grateful to Professor Eaton, Professor Mead and Dr Louka for their
thoughtful and well conducted work on these important cancers."
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
--------------------------------------
Dr Huw Jones CEO
--------------------------------------
Richard Moulson, CFO
--------------------------------------
finnCap www.finncap.com +44 (0) 20 7220 0500
--------------------------------------
Geoff Nash / Teddy Whiley (Corporate
Finance)
--------------------------------------
Alice Lane (ECM)
--------------------------------------
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
--------------------------------------
44 (0)7876 741 001 / +44 (0)7980 541
Anna Dunphy / Paul McManus 893
--------------------------------------
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The has its headquarters at Alderley Park, Cheshire , and its
registered office is at the Liverpool Science Park, Liverpool. It
is listed on the AIM market of the London Stock Exchange and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUUSNRAVUBAAR
(END) Dow Jones Newswires
July 13, 2021 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024